US Patent

US7919598 — Crystal structures of SGLT2 inhibitors and processes for preparing same

Composition of Matter · Assigned to Bristol Myers Squibb Co · Expires 2029-12-16 · 4y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects the physical crystal structures of a compound used in pharmaceutical compositions, including processes for preparing it and methods of treating diseases like diabetes.

USPTO Abstract

The present invention relates to physical crystal structures of a compound of the formula I: wherein R 1 , R 2 , R 2a , R 3 and R 4 are as defined herein, especially pharmaceutical compositions containing structures of compound I or II, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.

Drugs covered by this patent

Patent Metadata

Patent number
US7919598
Jurisdiction
US
Classification
Composition of Matter
Expires
2029-12-16
Drug substance claim
Yes
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.